Fierce Pharma
OCTOBER 17, 2024
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.
European Pharmaceutical Review
OCTOBER 17, 2024
In August 2024, the European Commission approved EURneffy (adrenaline nasal spray) in the EU as the first needle-free emergency option to treat anaphylaxis. This decision was granted a couple of weeks following approval by the US and Drug Administration (FDA). What are the main advantages of EURneffy over similar treatments? EURneffy was determined by the European Medicines Agency (EMA) to be interchangeable with injection products given it provides the comparable exposures to epinephrine (adren
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 17, 2024
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. | In a court decision filed in Washington, D.C., U.S. District Judge Dabney Friedrich rejected Novartis’ position that the FDA’s approval of MSN’s Entresto generic was unlawful. In issuing the decision, the judge upheld the green light that MSN won in July.
Healthcare Success
OCTOBER 17, 2024
Struggling with burnout while maintaining high-quality healthcare services that patients love? Tune in to our latest podcast as Lee Aase, founder of HELPCare, LLC, shares how he transitioned from his pioneering social media work at Mayo Clinic to lead an innovative membership-based direct-to-patient healthcare business. This podcast is a must-listen for healthcare leaders and primary care practitioners seeking innovative ways to enhance patient access, optimize care delivery, and address challen
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
OCTOBER 17, 2024
With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, younger people have become markedly
MedCity News
OCTOBER 17, 2024
CVS Health is reportedly exploring a breakup. But some experts aren’t sure if this is a good idea. The post Should CVS Health Break Up? appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
OCTOBER 17, 2024
The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the US Food and Drug Administration (FDA).
Fierce Pharma
OCTOBER 17, 2024
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. | Eli Lilly is making a series of investments in China. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.
MedCity News
OCTOBER 17, 2024
While federal healthcare programs focus their attention on ensuring healthcare resources exist for communities in need, HRSNs become critical drivers of whether individuals can actually access and benefit from these resources. The post Medicaid’s Health Equity Problem Starts and Ends with Health-Related Social Needs (HRSNs). Why Are They Being Overlooked?
PharmaVoice
OCTOBER 17, 2024
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
OCTOBER 17, 2024
The first human skin atlas is helping researchers to understand how skin forms, the mechanisms behind disorders, and could usher in scarless healing
MedCity News
OCTOBER 17, 2024
Now is a great time for employers to consider the impact GI health has on workplace equity and take steps to ensure they’re doing what they can to create an equitable workplace The post Gut Health Can Be a Workplace Equity Issue. Here’s How HR Leaders Can Prevent That appeared first on MedCity News.
pharmaphorum
OCTOBER 17, 2024
NICE backs NHS use of Roche's Alecensa as first adjuvant therapy for ALK+ NSCLC, and peri-operative use of MSD's Keytruda for all-comer NSCLC patients
MedCity News
OCTOBER 17, 2024
Sanofi’s equity investment in the new Orano Med entity comes a month after the pharmaceutical giant struck a €100 million deal to license a clinical-stage radiopharmaceutical developed for neuroendocrine tumors. Orano Med develops targeted cancer therapies based on lead-212, an alpha-emitting isotope. The post Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact With Orano appeared first on MedCity News.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
OCTOBER 17, 2024
Sage has launched another round of layoffs as it deals with the fallout of dropping a key pipeline drug for Alzheimer's and Parkinson's
Pharmaceutical Technology
OCTOBER 17, 2024
Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.
pharmaphorum
OCTOBER 17, 2024
Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy Leqembi, saying its efficacy does not outweigh its risks.
Clarivate
OCTOBER 17, 2024
In-licensing and acquisitions are fast tracks for pharmaceutical companies to access groundbreaking technologies and assets that will drive the next generation of transformative patient treatments. Dealmaking is not a trivial process. Audience members during the recent Clarivate webinar Emerging Deal Trends in Biotech and Pharma identified three of the biggest challenges they face when securing deals.
PharmaTimes
OCTOBER 17, 2024
The two-year programme will use virtual reality technology to teach essential skills
Clarivate
OCTOBER 17, 2024
Artificial intelligence (AI) already enhances a range of legal processes. From contract and due diligence reviews to e-discovery and legal research, early adopters of AI have seen undeniable benefits in speed, accuracy and efficiency. Today, AI promises many of the same benefits in the context of patent preparation and prosecution. However, between the decision to invest in AI-assisted patent drafting software and achieving a positive return on investment, a lot of hype and mischaracterization c
PharmaTimes
OCTOBER 17, 2024
The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma
Nixon Gwilt Law
OCTOBER 17, 2024
In late September 2024, the Office of Inspector General (OIG) issued a report recommending additional oversight of Remote Patient Monitoring (RPM) in Medicare. The report highlights key areas where OIG believes more safeguards and transparency are necessary to ensure RPM services are being properly utilized and billed. Below, we summarize the OIG’s main findings and explain why we believe certain recommendations may be unnecessary and could actually reduce patient access to remote monitoring ser
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharma Marketing Network
OCTOBER 17, 2024
As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. These trends are not only transforming how pharmaceutical companies engage with healthcare professionals and patients but also shaping the future of healthcare delivery. This article explores the top pharma marketing trends that are set to redefine the landscape in the coming years.
Nixon Gwilt Law
OCTOBER 17, 2024
In late September 2024, the Office of Inspector General (OIG) issued a report recommending additional oversight of Remote Patient Monitoring (RPM) in Medicare. The report highlights key areas where OIG believes more safeguards and transparency are necessary to ensure RPM services are being properly utilized and billed. Below, we summarize the OIG’s main findings and explain why we believe certain recommendations may be unnecessary and could actually reduce patient access to remote monitoring ser
Pharma Marketing Network
OCTOBER 17, 2024
In an increasingly competitive pharmaceutical landscape, the significance of healthcare branding has never been more pronounced. As we approach 2025, the ability of pharmaceutical companies to effectively craft and communicate their brand identity will play a pivotal role in determining their market success. This article delves into the essence of healthcare branding and explores strategic approaches for pharma marketing, emphasizing the importance of digital platforms and the measurement of bra
PharmExec
OCTOBER 17, 2024
Partnership is expected to develop radioligand therapies based on lead-212 alpha-emitting isotopes, which offer the opportunity to destroy cancer cells with minimal damage to healthy tissue.
Clarivate
OCTOBER 17, 2024
The Alethea Instructor Assistant is an AI-driven tool designed to streamline the creation of reading assignments for instructors. Guiding questions can boost student engagement with reading materials and foster critical thinking skills. Now available within Alethea , the Instructor Assistant enables educators to easily generate effective questions that bring reading assignments to life, seamlessly integrating into existing learning management system workflows.
Curzon Consulting
OCTOBER 17, 2024
17th October 2024 2 Minutes Curzon Consulting is thrilled to sponsor this year’s Alliance Manchester Business School Consultancy Case Competition. Introduced in 2016, the competition enables AMBS MBA students to showcase their skills, innovative thinking, and problem-solving abilities. It’s a platform that challenges them and provides them with real-world experience in tackling complex business scenarios in preparation for interview processes across a variety of industries.
PharmExec
OCTOBER 17, 2024
Vyalev is the first and only FDA-approved subcutaneous 24-hour infusion of a levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson disease.
European Pharmaceutical Review
OCTOBER 17, 2024
Sanofi Orano Med (subsidiary of the Orano Group) have agreed a new collaboration to advance development of next-generation radioligand therapies for rare cancers. As part of the agreement, the two parties will invest in a new entity, valued at €1.9 billion. It will operate under Orano Med and focus on creating and trialling next-generation lead-212 ( 212 Pb) radioligand therapies.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
313 
Let's personalize your content